Publication: 125

Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.

Citation:: J Clin Oncol vol 26 (15) 2457-63

Year:: 2008
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 799
Children:: None

Program:: OGC
Primary Committee:: Respiratory
Sec. Committees:

Pharmas:
Grants:: CA02599, CA03927, CA11789, CA12046, CA16450, CA21060, CA31946, CA33601, CA37135, CA41287, CA45418, CA45808, CA47559, CA47577

Corr. Author:
Authors:: Mark A Socinski A William Blackstock Jeffrey A Bogart Xiaofei Wang Michael Munley Julian Rosenman Lin Gu Gregory A Masters Peter Ungaro Arthur Sleeper Mark Green Antonius A Miller Everett E Vokes

Networks:

Study: CALGB-30105
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Combined Modality Therapy, Deoxycytidine, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Paclitaxel, Placebos, Prognosis, Radiography, Radiotherapy Dosage, Radiotherapy, Conformal, Remission Induction, Survival Rate, Thoracic Neoplasms